Andere Sprachen NGM Biopharmaceuticals, Inc.

Aktien

A2N7B5

US62921N1054

NGM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 04.04.2024			% 5 Tage	% 1. Jan.
1,54 ^USD	-1,28 %		0,00 %	+79,28 %

05.04.	The Column Group, LLC hat die Übernahme von 74% der Anteile an NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) von einer anderen Gruppe von Aktionären abgeschlossen.	CI
12.03.	NGM BIOPHARMACEUTICALS, INC. : Raymond James gibt eine neutrale Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NGM Bio Announces Closing of Tender Offer	05.04.
NGM Biopharmaceuticals, Inc.(NasdaqGM:NGM) dropped from NASDAQ Composite Index	05.04.
The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. from other group of shareholders.	05.04.
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P Global BMI Index	05.04.
NGM Biopharmaceuticals, Inc.(NasdaqGS:NGM) dropped from S&P TMI Index	05.04.
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting	19.03.
North American Morning Briefing : Investors -2-	18.03.
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM	13.03.
North American Morning Briefing : Stock Futures -2-	13.03.
NGM Biopharmaceuticals: Q4 Earnings Snapshot	11.03.
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11.03.
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results	11.03.
NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11.03.
North American Morning Briefing : Stock Futures -2-	11.03.
North American Morning Briefing : Fed's Preferred -2-	29.02.
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM	27.02.
Sector Update: Health Care Stocks Ease Late Afternoon	26.02.
Sector Update: Health Care Stocks Weaker Monday Afternoon	26.02.
Sector Update: Health Care	26.02.
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NGM Biopharmaceuticals, Inc.

Aktien

A2N7B5

US62921N1054

NGM

Andere Sprachen

Filter